X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2286) 2286
Book Review (340) 340
Newsletter (163) 163
Publication (94) 94
Conference Proceeding (55) 55
Newspaper Article (32) 32
Book Chapter (20) 20
Magazine Article (5) 5
Trade Publication Article (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ticagrelor (2436) 2436
clopidogrel (1605) 1605
index medicus (1204) 1204
humans (1003) 1003
prasugrel (983) 983
cardiac & cardiovascular systems (821) 821
acute coronary syndromes (589) 589
adenosine - analogs & derivatives (550) 550
male (525) 525
percutaneous coronary intervention (515) 515
acute coronary syndrome (496) 496
aspirin (494) 494
female (463) 463
platelet aggregation inhibitors - therapeutic use (419) 419
middle aged (395) 395
ticlopidine - analogs & derivatives (379) 379
coronary heart disease (371) 371
aged (366) 366
treatment outcome (360) 360
antiplatelet therapy (322) 322
care and treatment (316) 316
pharmacology & pharmacy (314) 314
platelet inhibition (303) 303
cardiac patients (299) 299
peripheral vascular disease (296) 296
acute coronary syndrome - drug therapy (291) 291
platelet aggregation inhibitors - adverse effects (275) 275
adenosine - therapeutic use (274) 274
myocardial infarction (260) 260
platelet aggregation inhibitors - administration & dosage (259) 259
cardiology (255) 255
risk factors (254) 254
research (243) 243
ticlopidine - therapeutic use (234) 234
purinergic p2y receptor antagonists - therapeutic use (230) 230
myocardial-infarction (225) 225
hematology (224) 224
outcomes (214) 214
analysis (213) 213
heart attacks (210) 210
intervention (208) 208
blood platelets (207) 207
mortality (205) 205
abridged index medicus (202) 202
thrombosis (200) 200
medical research (198) 198
adenosine - adverse effects (196) 196
drug therapy (195) 195
inhibition (193) 193
elevation myocardial-infarction (191) 191
adenosine - administration & dosage (190) 190
cardiovascular (190) 190
medicine, experimental (189) 189
cangrelor (180) 180
dosage and administration (179) 179
dual antiplatelet therapy (169) 169
transluminal angioplasty (169) 169
hemorrhage - chemically induced (163) 163
patients (162) 162
therapy (162) 162
purinergic p2y receptor antagonists - administration & dosage (161) 161
stroke (160) 160
trial (158) 158
purinergic p2y receptor antagonists - adverse effects (157) 157
bleeding (156) 156
heart attack (156) 156
blood platelets - drug effects (152) 152
drug therapy, combination (152) 152
acute myocardial-infarction (149) 149
double-blind (148) 148
medicine, general & internal (146) 146
aggregation (143) 143
cardiovascular diseases (143) 143
platelet reactivity (138) 138
clinical trials (137) 137
platelet aggregation - drug effects (137) 137
time factors (137) 137
prasugrel hydrochloride (136) 136
cardiovascular disease (131) 131
platelet aggregation inhibitors - pharmacology (131) 131
p2y (130) 130
adenosine (128) 128
management (127) 127
ticlopidine - adverse effects (126) 126
ticlopidine - administration & dosage (125) 125
coronary artery disease (123) 123
medicine & public health (122) 122
adult (121) 121
artery-disease (120) 120
prevention (120) 120
prospective studies (120) 120
risk (120) 120
aspirin - therapeutic use (118) 118
platelets (117) 117
pharmacokinetics (112) 112
platelet function tests (111) 111
safety (111) 111
adenosine - pharmacology (109) 109
association task-force (101) 101
coronary vessels (101) 101
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2370) 2370
German (37) 37
French (30) 30
Spanish (29) 29
Russian (16) 16
Czech (13) 13
Polish (12) 12
Korean (5) 5
Turkish (5) 5
Italian (4) 4
Portuguese (4) 4
Croatian (2) 2
Chinese (1) 1
Japanese (1) 1
Romanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular Revascularization Medicine, ISSN 1553-8389, 12/2018, Volume 19, Issue 8, pp. 897 - 898
Journal Article
Journal Article
LANCET, ISSN 0140-6736, 06/2019, Volume 393, Issue 10189, pp. 2393 - 2394
Journal Article
European Heart Journal, ISSN 0195-668X, 8/2009, Volume 30, Issue 16, pp. 1964 - 1977
Currently, clopidogrel is recommended for treatment of patients with acute coronary syndrome and/or percutaneous coronary intervention. However, the delayed... 
Prasugrel | Clopidogrel | Thienopyridine | Cangrelor | Ticagrelor | Purinoceptor P2Y
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2019, Volume 380, Issue 19, pp. 1825 - 1833
Journal Article
Circulation, ISSN 0009-7322, 2018, Volume 137, Issue 3, pp. 307 - 309
Journal Article
Journal of Thrombosis and Haemostasis, ISSN 1538-7933, 2009, Volume 7, Issue 9, pp. 1556 - 1565
Journal Article
Biological and Pharmaceutical Bulletin, ISSN 0918-6158, 2017, Volume 40, Issue 1, pp. 88 - 96
Ticagrelor is a direct-acting P2Y12 receptor antagonist. It is rapidly absorbed and partly metabolized to the active metabolite AR-C124910XX by CYP3A4 and... 
Journal Article
Circulation. Genomic and precision medicine, ISSN 2574-8300, 04/2018, Volume 11, Issue 4, pp. e002069 - e002069
BACKGROUND: CYP2C19 loss-of-function (LOF) alleles impair clopidogrel effectiveness after percutaneous coronary intervention. The feasibility, sustainability,... 
clopidogrel | percutaneous coronary intervention | acute coronary syndrome | genetic testing | cytochrome P-450 CYP2C19 | precision medicine | pharmacogenetics | CARDIAC & CARDIOVASCULAR SYSTEMS | MYOCARDIAL-INFARCTION | TICAGRELOR | GUIDELINES | IMPLEMENTATION | TRIAL | CLOPIDOGREL THERAPY | POLYMORPHISMS | TASK-FORCE | GENETICS & HEREDITY | ASSOCIATION | ARTERY-DISEASE | North Carolina | Predictive Value of Tests | Humans | Middle Aged | Male | Clopidogrel - administration & dosage | Feasibility Studies | Patient Selection | Percutaneous Coronary Intervention - instrumentation | Ticagrelor - adverse effects | Clinical Decision-Making | Platelet Aggregation Inhibitors - administration & dosage | Pharmacogenomic Variants | Ticagrelor - administration & dosage | Female | Retrospective Studies | Platelet Aggregation Inhibitors - metabolism | Prasugrel Hydrochloride - administration & dosage | Stents | Platelet Aggregation Inhibitors - adverse effects | Clopidogrel - metabolism | Coronary Disease - blood | Reproducibility of Results | Ticagrelor - metabolism | Risk Factors | Cytochrome P-450 CYP2C19 - genetics | Treatment Outcome | Prasugrel Hydrochloride - adverse effects | Coronary Disease - diagnosis | Pharmacogenomic Testing - methods | Prasugrel Hydrochloride - metabolism | Cytochrome P-450 CYP2C19 - metabolism | Aged | Clopidogrel - adverse effects | Coronary Disease - surgery | Aggregation | Blood platelets | Cytochrome P-450 | Genotype | Genetic aspects | Dosage and administration | Research | Cardiovascular diseases | Risk factors | Confidence intervals | Cerebrovascular system | Genotype & phenotype | Risk groups | Gene frequency | Angioplasty | Alleles | Clopidogrel | Bleeding | Clinical outcomes | Genotypes | Acute Coronary Syndromes | antiplatelet drug | pharmacogenetics cardiovascular disease | implementation | Atherosclerosis | Genetics | Pharmacology | cytochrome P450 enzymes
Journal Article
Clinical Cardiology, ISSN 0160-9289, 11/2018, Volume 41, Issue 11, pp. 1446 - 1454
Background Although switching between ticagrelor and clopidogrel is common in clinical practice, the efficacy and safety of this de-escalation remain... 
clopidogrel | STEMI | ticagrelor | de‐escalation | PCI | switch | de-escalation | OPTIMIZING CROSSOVER | CARDIAC & CARDIOVASCULAR SYSTEMS | DIPHOSPHATE RECEPTOR INHIBITORS | CONSENSUS | CONTEMPORARY PRACTICE | INSIGHTS | Drug Costs | Recurrence | Prospective Studies | Patient Readmission | Percutaneous Coronary Intervention - mortality | Humans | Middle Aged | Male | Clopidogrel - administration & dosage | ST Elevation Myocardial Infarction - economics | ST Elevation Myocardial Infarction - blood | Ticagrelor - economics | Ticagrelor - adverse effects | Time Factors | China | Platelet Aggregation Inhibitors - administration & dosage | Ticagrelor - administration & dosage | Female | Stroke - mortality | Clopidogrel - economics | Drug Substitution - adverse effects | Platelet Aggregation Inhibitors - adverse effects | Drug Substitution - mortality | Risk Factors | Treatment Outcome | Coronary Thrombosis - therapy | ST Elevation Myocardial Infarction - mortality | Stroke - etiology | ST Elevation Myocardial Infarction - surgery | Aged | Coronary Thrombosis - etiology | Clopidogrel - adverse effects | Hemorrhage - chemically induced | Percutaneous Coronary Intervention - adverse effects | Transluminal angioplasty | Care and treatment | Coronary artery bypass | Patient outcomes | Heart attack | Heart attacks | Heart surgery | Angioplasty | Stents | Index Medicus
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 08/2018, Volume 11, Issue 16, pp. 1576 - 1586
The study sought to assess whether treatment with ticagrelor, as compared with prasugrel and clopidogrel, improves endothelium-dependent dilation throughout... 
adenosine | endothelial function | P2Y12 inhibitors | prasugrel | ticagrelor
Journal Article
JACC: Cardiovascular Interventions, ISSN 1936-8798, 10/2017, Volume 10, Issue 20, pp. 2026 - 2028
Journal Article
Journal of Chromatographic Science, ISSN 0021-9665, 04/2019, Volume 57, Issue 4, pp. 331 - 338
Journal Article
Revista Espanola de Cardiologia, ISSN 0300-8932, 11/2017, Volume 70, Issue 11, pp. 952 - 959
Introduction and objectives The incorporation of the new antiplatelet agents (NAA) prasugrel and ticagrelor into routine clinical practice is irregular and... 
Prasugrel | Propensity score | Registry | Ticagrelor | Real world
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.